Neofordex

Unknown🇪🇺 European Union

EMA Page

Authorised Date: N/A
Approval ID: 6b237d0fb574a99d
Products: 1 listed
Opinion Adopted: N/A

Overview Summary

This is a summary of the European public assessment report (EPAR) for Neofordex. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Neofordex. For practical information about using Neofordex, patients should read the package leaflet or contact their doctor or pharmacist.

Therapeutic & Classification

Therapeutic Indication

### Therapeutic indication Treatment of multiple myeloma.

Therapeutic Area (MeSH)

N/A

ATC Code

H02AB02

ATC Item

dexamethasone

Pharmacotherapeutic Group

Corticosteroids for systemic use

Active Substances

Active Substance (Summary)

dexamethasone

INN / Common Names

N/A

Active Substance Details

Substance	CAS	Monograph
dexamethasone	N/A	地塞米松

Quick Info

Approval ID6b237d0fb574a99d

Product NumberN/A

StatusAuthorised

Authorised DateN/A

Opinion AdoptedN/A

Revision #N/A

Names & Aliases

EMA Name

Neofordex

Medicine Name

Neofordex

Aliases

N/A

Regulatory Flags

Orphan medicineUnknown

Generic medicineUnknown

BiosimilarUnknown

Conditional approvalUnknown

Exceptional circumstancesUnknown

Accelerated assessmentUnknown

Additional monitoringUnknown

Advanced therapyUnknown

Source Links

EMA Source

No risk management plan link.

Back to EMA Approvals